Androgen deprivation therapy ‘ups all-cause mortality risk’
Men receiving the therapy for prostate cancer are also more likely to experience adverse CV outcomes, researchers say
![](https://www.ausdoc.com.au/wp-content/uploads/2022/08/senior-man-patient-doctor-consult-dreamstime_s_59932847-1.jpg)
Patients with prostate cancer given primary androgen deprivation therapy have up to double the risk of major cardiac events and death than men receiving other treatments, a study shows.
Norwegian researchers say the likelihood of adverse outcomes was particularly high in those already at moderate risk of cardiovascular disease (CVD) and those with longer duration of treatment.